Skip to main content

Table 3 Risk factors for hospital mortality on ICU patients with candidaemia initially treated with fluconazole

From: Determinants of mortality in non-neutropenic ICU patients with candidaemia

Variable

Dying patients, n (%)

Surviving patients, n (%)

Univariate analysis*

Multivariate analysis**

   

Unadjusted HR (95% CI)

P

Adjusted HR (95% CI)

P

Age

  

1.03 (1.01 to 1.05)

0.001

1.03 (1.01 to 1.05)

0.002

Haemodialysis receipt

10/48 (21%)

4/45 (9%)

1.65 (0.82 to 3.32)

0.16

2.12 (1.03 to 4.35)

0.04

TPN receipt

30/48 (63%)

15/45 (33%)

1.90 (1.06 to 3.42)

0.03

  

Non-multitrauma patient

47/48 (98%)

33/45 (73%)

9.35 (1.29 to 67.84)

0.03

  

Ventilation day 1

40/48 (83%)

34/45 (76%)

1.28 (0.60 to 2.75)

0.52

  

Candida glabrata or Candida krusei

11/48 (23%)

3/45 (7%)

2.31 (1.17 to 4.56)

0.02

  

Time to fluconazole initiation

1.80 ± 1.29 days

2.51 ± 1.74 days

0.80 (0.65 to 0.98)

0.03

  

Fluconazole MIC (log10 transformed)

0.24 ± 0.74

0.10 ± 0.68

1.31 (0.90 to 1.90)

0.16

  

Fluconazole dose (log10 transformed)

2.66 ± 0.22

2.62 ± 0.21

1.89 (0.52 to 6.82)

0.33

  

Fluconazole dose: MIC (log10 transformed)

2.33 ± 0.22

2.45 ± 0.72

0.77 (0.54 to 1.11)

0.16

  
  1. CI = confidence interval; HR = hazard ratio; ICU = intensive care unit; MIC = minimum inhibitory concentration; TPN = total parenteral nutrition.